Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linggui Yangyuan Paste for male infertility (asthenozoospermia/oligoasthenozoospermia)
ChiCTR2300068556Phase 2Not yet recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Linggui Yangyuan Paste in male infertility, asthenospermia and oligoasthenospermia (OA) (2 arms), sponsored by Xiyuan Hospital. Primary endpoint: Total forward motility sperm count at week 12. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
Linggui Yangyuan Paste
03
Conditions
male infertilityasthenospermiaoligoasthenospermia (OA)
Beyond the preview
Go deeper on ChiCTR2300068556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068556.